Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
LAURUSLABS
Dr. Satyanarayana Chava M.Sc., Ph.D. · Hyderabad, India · 7,059 employees
₹1,781.30
▲+1.27%LAURUSLABS has surged ~119% off its 52-week low of 810 to sit within 1% of its high at 1781, defying its 'Hold' consensus on the back of 29% YoY revenue growth but at a stretched 88x earnings multiple that prices in sustained outsized expansion.
Exchange
NSI
Currency
INR
Day range
₹1,754.30 – ₹1,797.90
52-week range
₹810.05 – ₹1,797.90
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
At ~88x trailing earnings and near its 52-week high after a 119% rally from 810, the stock appears to have largely bid in the 29% YoY revenue growth trajectory, and fair value is likely meaningfully below current levels unless QoS margins and order book visibility expand further.
0.9% below the 1-year high · trend up
Hedge-fund memo
Today
Up 1.27% near the top of the day range (1797.9), trading in the upper third of its 1-year range with above-average volume (~30L), indicating continued conviction buying.
This week
The stock has likely held firm near highs over the week, buoyed by sector rotation into healthcare and pharma growth narratives.
This month
The multi-month rally from the 52-week low suggests a strong uptrend driven by improving API demand, CDMO wins, and pharma sector tailwinds.
Bull thesis
Bear thesis
News & sentiment
Bullish
8 headlines · 5 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 4 of 4 recent quarters (EPS actual vs. consensus).
6.8 vs 4.912
38.44% surprise
5.17 vs 4.97833
3.85% surprise
4.65 vs 3.68
26.36% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| LAURUSLABS | 962.46B | 88.05 | — | 25.39% | 29.10% |
| SYNGENE | 166.74B | 52.70 | 6.62% | 20.82% | 1.80% |
| GRANULES | 208.61B | 31.21 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
API raw-material cost spikes compress the 15% profit margin given high fixed-capacity model
Mitigation: Monitor cost of goods sold % trends quarterly; hedgeable input exposure is a function of specific APIs produced
USFDA/EU regulatory action on a key manufacturing facility disrupts supply to major customers
Mitigation: Track FDA inspection records, warning letters, and import alerts; diversification across facilities reduces single-point failure
Valuation contraction at 88x P/E if growth rate normalizes or sector rotation out of healthcare
Mitigation: Valuation discipline on entry; avoid adding to positions on momentum alone when P/E exceeds sector average substantially
Business intelligence
Competitive moat
Laurus's competitive moat rests on deep expertise in complex synthetic chemistry for high-barrier-to-entry APIs and intermediates, combined with established regulatory filings (DMFs/CEP) that raise switching costs for customers and differentiate it from lower-cost commodity API players in India.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
Catalyst calendar
CDMO order book / bookings visibility disclosure
Potential US-generic API contract wins from top-20 US generic pharma customers
USFDA or EU MHRA inspection results for current/expansion facilities
Thesis builder
Bull case
Laurus becomes the preferred CDMO partner in India for complex generics APIs, winning multi-year contracts that compound volumes and margins as US generics companies continue to reshore and diversify supply chains away from China.
Base case
Steady 20-25% revenue CAGR with gradual margin improvement as the company scales capacity utilisation, wins higher-margin custom synthesis, and benefits from the secular shift of global API production toward India.
Bear case
API pricing pressure, raw-material cost inflation, or a cyclical downturn in global generics demand compresses margins, and the elevated P/E gets repriced sharply if FY25 growth disappoints, taking the stock back toward 1200-1300.
Time horizon
12-24 months for the thesis to fully play out; the near-term is driven by order book conversion and margin trajectory rather than a step-change in valuation multiple.
Est. CAGR
18-25% revenue CAGR over the next 3-5 years (estimate based on current trajectory)
Entry (qual.)
Wait for a pullback to the 1300-1450 band or a clear post-earnings dip for a better risk-reward; entering near the 52-week high at current P/E is unattractive for fresh positions.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how LAURUSLABS fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain LAURUSLABS for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Hold — the stock has run hard and valuation is stretched; new buyers should wait for a meaningful pullback or clearer proof that 29% revenue growth can transition into proportionate margin expansion at current levels.
LatestLY·1d ago·positive stock performance
Upstox·2d ago·neutral price info
simplywall.st·3d ago·beat earnings forecasts
LatestLY·3d ago·record Q1 results surge
scanx.trade·5d ago·call recording available
TradingView·6d ago·record revenue profit growth
TradingView·6d ago·profit reported
TradingView·6d ago·weekly outlook
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
3.61 vs 2.5675
40.60% surprise
| 17.56% |
| 22.00% |
| DIVISLAB | 2.07T | 80.65 | 16.19% | 28.75% | 9.50% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,754.30
Resistance (day/52w high)
₹1,797.90
Volume
30,00,777
Trend
up
RSI (14)
85
MACD
bullish
MA cross
golden
50-day MA
₹1,467.47
200-day MA
₹1,152.77
vs 200-DMA
54.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Currency (INR/USD) headwinds on US-denominated contract receivables
Mitigation: Laurus likely natural-hedges portions of this; monitor forex hedging disclosures in filings
M&A / strategic moves
Exit (qual.)
Consider reducing fresh buys at these levels; existing holders should trim if valuation exceeds 95x forward P/E or if revenue growth decelerates below 20% in two consecutive quarters.
Overall conviction 75%